<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902134</url>
  </required_header>
  <id_info>
    <org_study_id>DEX-TRA-05</org_study_id>
    <secondary_id>2012-004548-31</secondary_id>
    <nct_id>NCT01902134</nct_id>
  </id_info>
  <brief_title>Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride</brief_title>
  <acronym>DAVID-art</acronym>
  <official_title>A Randomized, Double-blind, Placebo and Active-controlled, Parallel-group Study to Evaluate the Analgesic Efficacy and Safety of Dexketoprofen Trometamol and Tramadol Hydrochloride Oral Fixed Combination on Moderate to Severe Acute Pain After Elective Unilateral Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the analgesic efficacy of single and repeated doses of fixed
      combination of dexketoprofen trometamol (DKP) and tramadol hydrochloride (TRAM) in comparison
      to the single agents (and placebo for the single dose phase only) Approximately 600 male and
      female patients presenting moderate to severe pain after an elective primary hip arthroplasty
      are eligible to be randomised provided that they experience moderate to severe pain on the
      day after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical trial patients were randomized to the described 6 treatment arms, where each
      arm define the treatment to be received in the first single dose phase (lasting 8 hours after
      the 1st treatment intake) and in the subsequent multiple-dose phase (lasting from the second
      treatment intake up to the 8 hours after the last intake). Namely:

        -  DKP/TRAM followed by DKP/TRAM;

        -  DKP followed by DKP;

        -  TRAM followed by TRAM;

        -  placebo followed by DKP;

        -  placebo followed by TRAM;

        -  placebo followed by DKP/TRAM;

      The analyses of endpoints pertinent to the single dose phase were performed combining all the
      3 treatment arms including placebo into one group, which resulted in the following 4 analysis
      groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

      The analysis of endpoints pertinent to the multiple dose phase were performed combining the
      treatment arms including the same active treatment, which resulted in the following 3
      analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPID8 (Sum of Pain Intensity Differences Over 8 Hours)</measure>
    <time_frame>over 8 hours after the first dose</time_frame>
    <description>Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief.
The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)</measure>
    <time_frame>over 48 hours of the multiple-dose phase</time_frame>
    <description>Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase.
PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief.
The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)</measure>
    <time_frame>over 48 hours of the multiple-dose phase</time_frame>
    <description>Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS &lt; 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable),over 48 hours of the multiple-dose phase.
The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)</measure>
    <time_frame>over 8 hours after the first dose</time_frame>
    <description>Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores.
The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">641</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>DKP/TRAM followed by DKP/TRAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DKP followed by DKP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexketoprofen-single dose followed by Dexketoprofen-multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRAM followed by TRAM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tramadol-single dose followed by Tramadol-multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by DKP/TRAM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by DKP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo single dose followed by Dexketoprofen-multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by TRAM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo single dose followed by Tramadol-multiple doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo single oral dose (first 8 hours)</description>
    <arm_group_label>Placebo followed by DKP/TRAM</arm_group_label>
    <arm_group_label>Placebo followed by DKP</arm_group_label>
    <arm_group_label>Placebo followed by TRAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol-single dose</intervention_name>
    <description>Tramadol single oral dose (first 8 hours)</description>
    <arm_group_label>TRAM followed by TRAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen-single dose</intervention_name>
    <description>Dexketoprofen single oral dose (first 8 hours)</description>
    <arm_group_label>DKP followed by DKP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen/Tramadol-single dose</intervention_name>
    <description>Dexketoprofen/Tramadol oral single dose (first 8 hours)</description>
    <arm_group_label>DKP/TRAM followed by DKP/TRAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol-multiple doses</intervention_name>
    <description>Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)</description>
    <arm_group_label>TRAM followed by TRAM</arm_group_label>
    <arm_group_label>Placebo followed by TRAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen-multiple doses</intervention_name>
    <description>Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)</description>
    <arm_group_label>DKP followed by DKP</arm_group_label>
    <arm_group_label>Placebo followed by DKP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen/Tramadol-multiple doses</intervention_name>
    <description>Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)</description>
    <arm_group_label>DKP/TRAM followed by DKP/TRAM</arm_group_label>
    <arm_group_label>Placebo followed by DKP/TRAM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged 18 to 80 years. Females participating in the study must
             be either of non-childbearing potential, or willing to use a highly effective
             contraceptive method.

          -  Scheduled to undergo standard primary (first-time) one-sided total hip replacement
             surgery due to primary osteoarthritis.

          -  Patients experiencing pain at rest of at least moderate intensity the day after
             surgery.

        Exclusion Criteria:

          -  Patients not suitable for study treatments and rescue medication (RM) or those for
             whom non-steroidal anti-inflammatory drugs (NSAIDs), opioids, acetyl salicylic acid,
             pyrazolones or pyrazolidines are contraindicated.

          -  Patients with clinically significant abnormalities in vital signs, safety laboratory
             tests and 12-lead ECG at screening.

          -  Patients with history of any illness or condition that might pose a risk to the
             patient or confound the efficacy and safety study results.

          -  Patients using and not suitable to withdraw analgesics other than those specified in
             the protocol.

          -  Patients using and not suitable for withdrawing any of the prohibited medication
             specified in the protocol.

          -  Pregnant and breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Moore, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Pain Research &amp; Nuffield Department of Anaesthetics - University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry J McQuay, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Balliol College Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urazova nemocnice v Brne</name>
      <address>
        <city>Brno</city>
        <zip>662 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava, p.o.</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oblastni nemocnice Kladno</name>
      <address>
        <city>Kladno</city>
        <zip>272 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oblastni nemocnice Mlada Boleslav a.s.</name>
      <address>
        <city>Mlada Boleslav</city>
        <zip>293 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Hospital, Department of Orthopaedics</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE KK Trauma Központ-Balesetsebészeti és Kézsebésze</name>
      <address>
        <city>Pécs</city>
        <zip>7632</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MÁV Kórház és Rendelőintézet, Ortopédiai osztály</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejér Megyei Szent György Kórház</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liepaja Regional Hospital</name>
      <address>
        <city>Liepaja</city>
        <zip>LV-3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga's 2nd Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1004</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Traumatology and Orthopaedics</name>
      <address>
        <city>Riga</city>
        <zip>LV-1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidzemes Hospital</name>
      <address>
        <city>Valmiera</city>
        <zip>LV-4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaunas Clinical Hospital</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-44320</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kaunas</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipedos Universitetine ligonine</name>
      <address>
        <city>Klaipeda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respublikine Vilniaus universitetine ligonine</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-04130</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Klioniczny w Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warminskie Centrum Ortopedyczne</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Szpital im. E. Szczeklika</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urazowo - Ortopedycznej Wojewodzkiego Szpitala Specjalistycznego we Wrocławiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-128</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz</name>
      <address>
        <city>Lodz</city>
        <state>Łódzkie</state>
        <zip>91-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for orthopedic Surgery Banjica [Ortopedic Surgery</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Orthopedic Surgery and Trauma Bul. Dr Zorana Djindjica</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital L'Esperança. Parc de Salut Mar.</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital [Orthopedic]</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuang Tien General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>433</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkaska oblasna likarnia</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut patologii khrebta ta suglobiv im. prof. M.I. Sytenka NAMN Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyivska oblasna klinichna likarnia</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sevastopolska miska likarnia №9</name>
      <address>
        <city>Sevastopol</city>
        <zip>99018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://bja.oxfordjournals.org/content/116/2/269.long</url>
  </link>
  <results_reference>
    <citation>McQuay HJ, Moore RA, Berta A, Gainutdinovs O, Fülesdi B, Porvaneckas N, Petronis S, Mitkovic M, Bucsi L, Samson L, Zegunis V, Ankin ML, Bertolotti M, Pizà-Vallespir B, Cuadripani S, Contini MP, Nizzardo A. Randomized clinical trial of dexketoprofen/tramadol 25 mg/75 mg in moderate-to-severe pain after total hip arthroplasty. Br J Anaesth. 2016 Feb;116(2):269-76. doi: 10.1093/bja/aev457.</citation>
    <PMID>26787797</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <results_first_submitted>February 6, 2015</results_first_submitted>
  <results_first_submitted_qc>March 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2015</results_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe acute pain</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Hip arthroplasty</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Dexketoprofen</keyword>
  <keyword>Tramadol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Dexketoprofen trometamol</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DKP/TRAM Followed by DKP/TRAM</title>
          <description>Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses</description>
        </group>
        <group group_id="P2">
          <title>DKP Followed by DKP</title>
          <description>Dexketoprofen-single dose followed by Dexketoprofen-multiple doses</description>
        </group>
        <group group_id="P3">
          <title>TRAM Followed by TRAM</title>
          <description>Tramadol-single dose followed by Tramadol-multiple doses</description>
        </group>
        <group group_id="P4">
          <title>Placebo Followed by DKP/TRAM</title>
          <description>Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses</description>
        </group>
        <group group_id="P5">
          <title>Placebo Followed by DKP</title>
          <description>Placebo single dose followed by Dexketoprofen-multiple doses Placebo followed by DKP</description>
        </group>
        <group group_id="P6">
          <title>Placebo Followed by TRAM</title>
          <description>Placebo single dose followed by Tramadol-multiple doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="53"/>
                <participants group_id="P6" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Single-dose Phase</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="53"/>
                <participants group_id="P6" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Multiple-dose Phase</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="53"/>
                <participants group_id="P6" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="145"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat (ITT) population (which includes all patients randomized).</population>
      <group_list>
        <group group_id="B1">
          <title>DKP/TRAM Followed by DKP/TRAM</title>
          <description>Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses</description>
        </group>
        <group group_id="B2">
          <title>DKP Followed by DKP</title>
          <description>Dexketoprofen-single dose followed by Dexketoprofen-multiple doses</description>
        </group>
        <group group_id="B3">
          <title>TRAM Followed by TRAM</title>
          <description>Tramadol-single dose followed by Tramadol-multiple doses</description>
        </group>
        <group group_id="B4">
          <title>Placebo Followed by DKP/TRAM</title>
          <description>Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses</description>
        </group>
        <group group_id="B5">
          <title>Placebo Followed by DKP</title>
          <description>Placebo single dose followed by Dexketoprofen-multiple doses</description>
        </group>
        <group group_id="B6">
          <title>Placebo Followed by TRAM</title>
          <description>Placebo single dose followed by Tramadol-multiple doses</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="159"/>
            <count group_id="B2" value="161"/>
            <count group_id="B3" value="160"/>
            <count group_id="B4" value="54"/>
            <count group_id="B5" value="53"/>
            <count group_id="B6" value="54"/>
            <count group_id="B7" value="641"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="10.43"/>
                    <measurement group_id="B2" value="63.3" spread="9.01"/>
                    <measurement group_id="B3" value="61.3" spread="9.68"/>
                    <measurement group_id="B4" value="63.9" spread="9.0"/>
                    <measurement group_id="B5" value="61.0" spread="11.10"/>
                    <measurement group_id="B6" value="59.8" spread="11.30"/>
                    <measurement group_id="B7" value="61.9" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.3" spread="15.37"/>
                    <measurement group_id="B2" value="81.4" spread="15.63"/>
                    <measurement group_id="B3" value="83.5" spread="17.25"/>
                    <measurement group_id="B4" value="82.4" spread="15.91"/>
                    <measurement group_id="B5" value="81.7" spread="13.77"/>
                    <measurement group_id="B6" value="82.1" spread="15.27"/>
                    <measurement group_id="B7" value="82.6" spread="15.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.8" spread="8.99"/>
                    <measurement group_id="B2" value="167.9" spread="9.14"/>
                    <measurement group_id="B3" value="169.1" spread="9.20"/>
                    <measurement group_id="B4" value="166.1" spread="8.47"/>
                    <measurement group_id="B5" value="168.0" spread="9.49"/>
                    <measurement group_id="B6" value="169.9" spread="7.94"/>
                    <measurement group_id="B7" value="168.5" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SPID8 (Sum of Pain Intensity Differences Over 8 Hours)</title>
        <description>Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief.
The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.</description>
        <time_frame>over 8 hours after the first dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DKP/TRAM</title>
            <description>Drug: Dexketoprofen/Tramadol single oral dose (first 8 hours); Arm type: experimental; Dexketoprofen/Tramadol single oral dose (first 8 hours);</description>
          </group>
          <group group_id="O2">
            <title>DEXKETOPROFEN</title>
            <description>Drug: Dexketoprofen single oral dose (first 8 hours); Arm type: active comparator; Dexketoprofen single oral dose (first 8 hours);</description>
          </group>
          <group group_id="O3">
            <title>TRAMADOL</title>
            <description>Drug: Tramadol single oral dose (first 8 hours); Arm type: active comparator; Tramadol single oral dose (first 8 hours);</description>
          </group>
          <group group_id="O4">
            <title>PLACEBO</title>
            <description>Drug: Placebo; Arm type: PLACEBO comparator; Placebo single oral dose (first 8 hours);</description>
          </group>
        </group_list>
        <measure>
          <title>SPID8 (Sum of Pain Intensity Differences Over 8 Hours)</title>
          <description>Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief.
The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.9" spread="156.50"/>
                    <measurement group_id="O2" value="208.8" spread="154.69"/>
                    <measurement group_id="O3" value="204.6" spread="145.79"/>
                    <measurement group_id="O4" value="151.1" spread="158.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)</title>
        <description>Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase.
PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief.
The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.</description>
        <time_frame>over 48 hours of the multiple-dose phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DKP/TRAM</title>
            <description>Drug: Dexketoprofen/Tramadol multiple doses; Arm type: experimental; Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (a total of 12 doses)</description>
          </group>
          <group group_id="O2">
            <title>DEXKETOPROFEN</title>
            <description>Drug: Dexketoprofen multiple doses; Arm type: active comparator; Dexketoprofen multiple oral doses t.i.d. for 5 days (a total of 12 doses)</description>
          </group>
          <group group_id="O3">
            <title>TRAMADOL</title>
            <description>Drug: Tramadol multiple doses; Arm type: active comparator; Tramadol multiple oral doses t.i.d. for 5 days (a total of 12 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)</title>
          <description>Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase.
PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief.
The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1943.7" spread="1000.51"/>
                    <measurement group_id="O2" value="1677.5" spread="1070.91"/>
                    <measurement group_id="O3" value="1765.6" spread="963.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders According to PI-VAS (Pain Intensity – Visual Analogue Scale)</title>
        <description>Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS &lt; 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable),over 48 hours of the multiple-dose phase.
The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.</description>
        <time_frame>over 48 hours of the multiple-dose phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DKP/TRAM</title>
            <description>Drug: Dexketoprofen/Tramadol multiple doses; Arm type: experimental; Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (a total of 12 doses)</description>
          </group>
          <group group_id="O2">
            <title>DEXKETOPROFEN</title>
            <description>Drug: Dexketoprofen multiple doses; Arm type: active comparator; Dexketoprofen multiple oral doses t.i.d. for 5 days (a total of 12 doses)</description>
          </group>
          <group group_id="O3">
            <title>TRAMADOL</title>
            <description>Drug: Tramadol multiple doses; Arm type: active comparator; Tramadol multiple oral doses t.i.d. for 5 days (a total of 12 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders According to PI-VAS (Pain Intensity – Visual Analogue Scale)</title>
          <description>Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS &lt; 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable),over 48 hours of the multiple-dose phase.
The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1"/>
                    <measurement group_id="O2" value="76.6"/>
                    <measurement group_id="O3" value="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)</title>
        <description>Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief – Verbal Rating Scale: pain relief 0=none, 4=complete) scores.
The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.</description>
        <time_frame>over 8 hours after the first dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DKP/TRAM</title>
            <description>Drug: Dexketoprofen/Tramadol single oral dose (first 8 hours); Arm type: experimental; Dexketoprofen/Tramadol single oral dose (first 8 hours);</description>
          </group>
          <group group_id="O2">
            <title>DEXKETOPROFEN</title>
            <description>Drug: Dexketoprofen single oral dose (first 8 hours); Arm type: active comparator; Dexketoprofen single oral dose (first 8 hours);</description>
          </group>
          <group group_id="O3">
            <title>TRAMADOL</title>
            <description>Drug: Tramadol single oral dose (first 8 hours); Arm type: active comparator; Tramadol single oral dose (first 8 hours);</description>
          </group>
          <group group_id="O4">
            <title>PLACEBO</title>
            <description>Drug: Placebo; Arm type: PLACEBO comparator; Placebo single oral dose during single dose phase (first 8 hours);</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)</title>
          <description>Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief – Verbal Rating Scale: pain relief 0=none, 4=complete) scores.
The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9"/>
                    <measurement group_id="O2" value="56.5"/>
                    <measurement group_id="O3" value="51.9"/>
                    <measurement group_id="O4" value="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study duration for patients was up to 6 weeks.</time_frame>
      <desc>Analyzed for the Safety population (all randomized patients who received at least one dose of the study treatment). Includes adverse events emerging after at least one dose of active study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>DKP/TRAM Followed by DKP/TRAM</title>
          <description>Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses.</description>
        </group>
        <group group_id="E2">
          <title>DKP Followed by DKP</title>
          <description>Dexketoprofen-single dose followed by Dexketoprofen-multiple doses.</description>
        </group>
        <group group_id="E3">
          <title>TRAM Followed by TRAM</title>
          <description>Tramadol-single dose followed by Tramadol-multiple doses.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Followed by DKP/TRAM</title>
          <description>Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses.</description>
        </group>
        <group group_id="E5">
          <title>Placebo Followed by DKP</title>
          <description>Placebo single dose followed by Dexketoprofen-multiple doses.</description>
        </group>
        <group group_id="E6">
          <title>Placebo Followed by TRAM</title>
          <description>Placebo single dose followed by Tramadol-multiple doses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bone operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Heart valve replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Vascular graft</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting the results of this study for publication or presentation, the PI will allow the Sponsor at least 60 days to review and comment upon the publication manuscript. The Sponsor will provide any manuscript of the results of this study at least 60 days before publishing to the authors for a complete review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Angela Capriati, Corporate Director of Clinical Research</name_or_title>
      <organization>Menarini Ricerche S.p.A.</organization>
      <phone>+3905556809933</phone>
      <email>ACapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

